San Diego-based Arena Pharmaceuticals (NASDAQ: [[ticker:ARNA]]) said today it has filed its application to the FDA for clearance to start marketing lorcaserin for weight loss. The application includes information on 18 clinical trials that enrolled almost 8,600 patients, including the pivotal trials known as Bloom and Blossom. The company had forecasted previously it would complete the application by the end of 2009.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
